ULBI Ultralife

Ultralife Corporation to Report Second Quarter Results on July 27, 2023  

Ultralife Corporation to Report Second Quarter Results on July 27, 2023  

NEWARK, N.Y., July 13, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) will report its second quarter results for the period ended June 30, 2023 before the market opens on Thursday, July 27, 2023.

Ultralife’s Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on July 27, 2023.   Please see the call-in procedures which follow below.

NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE:

To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: . This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again.

A live webcast of the conference call will be available to investors in the Events & Presentations Section of the Company’s website at . For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include: Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit .

Company Contact:      Investor Relations Contact:
Ultralife CorporationLHA
Philip A. Fain     Jody Burfening    
(315) 210-6110(212) 838-3777



EN
13/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultralife

Ultralife Corp: 1 director

A director at Ultralife Corp bought 53,000 shares at 5.677USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch